COMMUNITY CLINCIAL ONCOLOGY PROGRAM

Natalie Warren Bryant癌症中心（NWBCC）是一个目前资助的 社区临床肿瘤学计划（CCOP）是一个物理和 俄克拉荷马州塔尔萨的圣弗朗西斯医院的行政组成部分。 圣弗朗西斯医院是一家拥有750张床位的非营利性教学医院， 俄克拉荷马州东北部和堪萨斯部分地区的160万居民， 密苏里州和阿肯色州。NWBCC是美国最大的癌症护理提供者， 该地区每年约有1 500名新癌症患者登记。 该计划与ECOG有着13年的合作关系， 平均每年增加90-100例患者。由于缔约方会议协商委员会的资助， 也与M.D.建立了联系。安德森和NSABP。 NWCC CCOP现在申请继续作为一个双组成部分计划 由NWBCC/圣弗朗西斯和癌症护理协会组成，靠近 医院校园癌症护理协会是核心调查人员， 在过去的11年里负责癌症项目的发展。两 NWBCC ECOG附属机构、Hillcrest医疗中心和塔尔萨地区医疗中心 中心（原俄克拉荷马州骨科医院）已被添加， 到NWBC-CCOP真正的全市参与NCI批准的临床 预计将增加172名患者的试验和癌症控制项目 治疗方案和557项癌症控制研究。分析 患者日志显示，NWBCC-CCOP将40%符合条件的新 在NCI批准的试验中的患者，除了我们自己的内部累积外， 调查事务所

The Natalie Warren Bryant Cancer Center (NWBCC) is a currently funded Community Clinical Oncology Program (CCOP) which is a physical and administrative component of Saint Francis Hospital in Tulsa, Oklahoma. Saint Francis Hospital is a 750 bed non-profit teaching hospital serving the 1.6 million residents of Northeastern Oklahoma and portions of Kansas, Missouri, and Arkansas. The NWBCC is the largest provider of cancer care in the area and registers approximately 1,500 new cancer patients annually. The program has enjoyed a thirteen year relationship with ECOG with an average patient accrual of 90-100 per year. As a result of CCOP funding, affiliations have also been established with M.D. Anderson and NSABP. The NWBCC CCOP is now applying for continuation as a dual component program consisting of NWBCC/Saint Francis and Cancer Care Associates, near the hospital campus. Cancer Care Associates are the core investigators responsible for cancer program development for the past eleven years. Two NWBCC ECOG affiliates, Hillcrest Medical Center and Tulsa Regional Medical Center (formerly Oklahoma Osteopathic Hospital) have been added, bringing to the NWBCC-CCOP true city-wide participation in NCI-approved clinical trials and cancer control projects with anticipated accrual of 172 patients to the treatment protocols and 557 to cancer control studies. Analysis of patient logs has shown that the NWBCC-CCOP places 40% of eligible new patients on NCI-approved trials, in addition to accrual to our own in-house investigations.